<a href="https://www.fiercebiotech.com/biotech/gilead-scraps-lead-arthritis-drug-405m-mirobio-buyout-latest-blow-btla-field" hreflang="en">Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field</a>
Gilead Sciences has discontinued the development of GS-0272, its lead arthritis drug acquired from MiroBio, following a review of available data, marking a setback for the BTLA agonist field. This decision reflects Gilead's strategy to focus on more promising programs, although another asset from the MiroBio deal, GS-0151, remains in development.
For a professional tracking healthtech and biotech investment opportunities, the key insight is that Gilead's decision to scrap its BTLA agonist GS-0272, after acquiring MiroBio for $405 million, highlights the challenges and inherent risks in developing immune checkpoint agonists for inflammatory diseases. This serves as a cautionary signal for investments in similar immune-modulating therapies, indicating a need for thorough evaluation of clinical data and pipeline viability before significant financial commitments.